BioWorld

Nov. 6, 2006

View Archived Issues

VaxGen Shares Nosedive On Anthrax Vaccine Stall

The latest snag for VaxGen's anthrax vaccine sent shares down by more than half after the company said the FDA put rPA102 on clinical hold, delaying the second Phase II trial. (BioWorld Today) Read More

Adventrx Adding $40M For Cancer, Anti-Infective Work

Read More

Smell Of Dollars Burning On Breeze Of Pre-Election

Read More

Switch In Congress Could Start Drug Pricing Scrutiny

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More